Shanghai S.E.
06:00:00 2024-05-16 pm EDT
5-day change
1st Jan Change
12.82
CNY
+0.08%
-0.62%
-16.21%
Lafang China Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
April 27, 2021 at 11:31 pm EDT
Lafang China Co.,Ltd announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 245.035 million compared to CNY 167.221 million a year ago. Operating income was CNY 20.263 million compared to CNY 19.451 million a year ago. Net income was CNY 16.755 million compared to CNY 16.121 million a year ago. Basic earnings per share from continuing operations was CNY 0.07 compared to CNY 0.07 a year ago.
Lafang China Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 29
CI
Lafang China Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 29
CI
Tranche Update on Lafang China Co.,Ltd's Equity Buyback Plan announced on September 27, 2023.
Jan. 02
CI
Lafang China Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
Lafang China Co.,Ltd announces an Equity Buyback for CNY 40 million worth of its shares.
23-09-26
CI
Lafang China Co.,Ltd authorizes a Buyback Plan.
23-09-21
CI
Lafang China Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-28
CI
Lafang China Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Lafang China Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-28
CI
Lafang China Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-28
CI
Lafang China Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-29
CI
Aesthetic Medical International Holdings Group Limited announced that it has received CNY 99.999999 million in funding from Lafang China Co.,Ltd, Hawyu (HK) Limited
22-07-12
CI
Lafang China Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-27
CI
Lafang China Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
22-04-27
CI
Lafang China Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-29
CI
Lafang China Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-26
CI
China stocks close higher as banking, energy firms climb
21-06-22
RE
Aesthetic Medical International Holdings Group Limited announced that it expects to receive CNY 98.91385 million in funding from Lafang China Co.,Ltd, Hawyu (HK) Limited
21-05-15
CI
Lafang China Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-27
CI
Lafang China Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-30
CI
Lafang China Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2020
20-08-28
CI
Lafang China Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020
20-04-28
CI
Lafang China Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2019
20-04-16
CI
Certain A Shares of Lafang China Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-MAR-2020.
20-03-12
CI
Lafang China Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2019
19-10-29
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
LAFANG CHINA CO., LTD. is principally engaged in research and development, manufacture and sales of household and personal care chemical products. The Company's main products include shampoo, conditioner, body wash, toilet soaps and creams. The Company owns several brands such as Lafang, Yujie, Binchun, Meiduosi and Shengfeng, among others.
More about the company
1st Jan change
Capi.
-16.21% 400M +10.07% 45.22B -2.88% 19.19B +3.08% 3.62B +4.92% 2.66B -13.30% 1.57B +55.34% 1.4B +21.59% 994M +22.95% 829M +24.76% 439M
Sanitary Products
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
LAFANG CHINA CO.,LTD 
